IDEV - ETF AI Analysis
Top Page
iShares Core MSCI International Developed Markets ETF (IDEV)
IDEV, the iShares Core MSCI International Developed Markets ETF, has a solid overall rating driven mainly by strong, diversified holdings in global leaders like HSBC, Novartis, and AstraZeneca, which show healthy financial performance, reasonable valuations, and positive business outlooks. Some positions such as SAP and Shell introduce risks through weaker technical trends or growth challenges, but they are balanced by the broader mix of stable banks, healthcare, and consumer staples. The main risk factor is exposure to individual stocks with signs of overvaluation or overbought conditions, which could lead to short-term volatility even within this diversified international portfolio.
IDEV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 34.00B
- Region
- Developed Markets
- Expense Ratio
- 0.04%
- Beta
- 0.74
- Issuer
- iShares
- Inception Date
- Mar 21, 2017
- Dividend Yield
- 3.22%
- Asset Class
- Equity
- Index Tracked
- MSCI World ex USA IMI
IDEV Summary
IDEV is an ETF that tracks the MSCI World ex USA IMI index, giving you broad exposure to stocks in developed countries outside the U.S. and Canada. It owns thousands of companies across many sectors and regions, including well-known names like Nestlé and ASML. Investors might consider IDEV to diversify beyond the U.S. market and tap into long-term growth in Europe, Japan, and other developed economies. A key risk is that international stocks can be volatile and are affected by currency swings and global events, so the value of the ETF can go up and down over time.
How much will it cost me?
The iShares Core MSCI International Developed Markets ETF (IDEV) has an expense ratio of 0.04%, meaning you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically costs less to operate compared to actively managed funds.
What would affect this ETF?
Positive drivers for IDEV could include economic growth in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare, which are heavily represented in the ETF. However, negative factors such as rising interest rates or geopolitical tensions in Europe and Asia could impact the performance of key holdings like ASML, Nestlé, and HSBC, as well as broader sector trends like energy and industrials. Regulatory changes or currency fluctuations in these regions may also affect returns.
IDEV Top 10 Holdings
IDEV leans heavily on international blue chips, with Dutch chip-equipment giant ASML acting as a key engine of long-term gains despite some recent choppiness. Big European banks like HSBC and Mitsubishi UFJ add a financial backbone, generally rising but with bouts of short-term softness. Shell has been a bright spot, giving the fund an energy tailwind, while defensive names like Roche and Novartis keep returns steadier. Nestlé and AstraZeneca, however, have been losing steam, modestly dragging performance. Overall, it’s a diversified, developed-markets ex-U.S. mix with no single sector dominating.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 2.14% | $718.99M | EUR 570.61B | 63.15% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:HSBA | HSBC Holdings | 1.11% | $372.04M | GBP 237.35B | 37.89% | 80Outperform |
 GB:SHEL | Shell (UK) | 1.07% | $359.42M | GBP 221.86B | 40.84% | 73Outperform |
 CH:NOVN | Novartis AG | 1.01% | $338.05M | CHF 232.26B | 22.91% | 80Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 CH:NESN | Nestlé SA | 0.93% | $313.38M | CHF 213.78B | 3.09% | 71Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 JP:8306 | Mitsubishi UFJ Financial Group | 0.81% | $270.91M | JPY 37.72T | 47.94% | 76Outperform |
 DE:SAP | SAP SE | 0.86% | $288.36M | EUR 235.32B | -9.08% | 66Neutral |
IDEV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDEV, the sentiment is Negative. The current price of 89.16 is below the 20-day moving average (MA) of 89.44, below the 50-day MA of 91.13, and above the 200-day MA of 88.06, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 62.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDEV.
IDEV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IDEV | $89.16 | $97.00(8.79% Upside) | $34.00B | 0.04% | 66Neutral |
 VEA | $69.26 | $88.56(27.87% Upside) | $230.36B | 0.03% | 58Neutral |
 SCHF | $26.88 | $34.09(26.81% Upside) | $67.84B | 0.03% | 60Neutral |
 SPDW | $49.21 | $60.79(23.54% Upside) | $41.22B | 0.03% | 60Neutral |
 AVDE | $89.24 | $111.37(24.79% Upside) | $19.59B | 0.23% | 65Neutral |
 DFAI | $41.41 | $50.33(21.55% Upside) | $18.24B | 0.18% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IDEV | iShares Core MSCI International Developed Markets ETF | 89.16 | 10.07 | 12.74% | |
| VEA | Vanguard FTSE Developed Markets ETF | 69.26 | 9.19 | 15.29% | |
| SCHF | Schwab International Equity ETF | 26.88 | 3.66 | 15.76% | |
| SPDW | SPDR Portfolio Developed World ex-US ETF | 49.21 | 6.57 | 15.42% | |
| AVDE | Avantis International Equity ETF | 89.24 | 11.25 | 14.43% | |
| DFAI | Dimensional International Core Equity Market ETF | 41.41 | 5.22 | 14.44% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.